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Purpose: The glutathione-S-transferase (GST)P1, GSTM1, and GSTT1 genotypes have 
been associated with an increased risk of prostate, bladder, and lung cancers. The aim 
of this study was to investigate the association between the GSTP1, GSTM1, and 
GSTT1 genotypes and the risk of prostate cancer in Korean men.
Materials and Methods: The study group consisted of 166 patients with histologically 
confirmed prostate cancer. The control group consisted of 327 healthy, cancer-free in-
dividuals. The diagnosis of prostate cancer was made by transrectal ultrasound-guided 
biopsy. Patients with prostatic adenocarcinoma were divided into organ-confined (≤
pT2) and non-organ-confined (≥pT3) subgroups. The histological grades were sub-
divided according to the Gleason score. The GSTP1, GSTM1, and GSTT1 genotypes 
were determined by using polymerase chain reaction-based methods. The relationship 
among GSTP1, GSTM1, and GSTT1 polymorphisms and prostate cancer in a case-con-
trol study was investigated. 
Results: The frequency of the GSTM1 null genotype in the prostate cancer group (54.2%) 
was higher than in the control group (odds ratio=1.53, 95% confidence interval=1.20- 
1.96). The comparison of the GSTP1, GSTM1, and GSTT1 genotypes and cancer prog-
nostic factors, such as staging and grading, showed no statistical significance.
Conclusions: An increased risk for prostate cancer may be associated with the GSTM1
null genotype in Korean men, but no association was found with the GSTT1 or GSTP1
genotypes.
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INTRODUCTION
The biotransformation enzymes, glutathione-S-transferases 
(GSTs), are members of a multigene family; their gene pro-
ducts are phase II enzymes with both catalytic activities, 
including glutathione conjugation of electrophiles, and 
noncatalytic functions. The presumed function of these en-
zymes is to protect tissues against toxic and carcinogenic 
compounds that enter the body as either food additives or 
drugs [1]. In addition to their catalytic activities, GSTs are 
thought to engage metabolites and steroid hormones, which 
are important determinants in the development of prostate 
cancer [2,3]. The GSTs are involved in the detoxification 
of electrophilic compounds (such as carcinogens and cyto-
toxic drugs) by glutathione conjugation [4,5]. In addition, 
these enzymes are thought to play a role in the protection 
of DNA from oxidative damage [6]. GSTP1 inactivation 
may lead to increased cell vulnerability to oxidative DNA 
damage and to the accumulation of DNA base adducts, 
which allows tumors to acquire other relevant genetic al-
terations during prostate carcinogenesis [7].
　GSTM1 detoxifies carcinogenic polycyclic aromatic hy-Korean J Urol 2011;52:247-252
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TABLE 1. Distribution of the prostate cancer patients and controls
according to age
Age (yr) No. of prostate cancer (%) No. of control (%)
50-59 17 (10.24)   79 (24.23)
60-69 68 (40.96)   70 (21.47)
70-79 58 (34.94) 131 (40.18)
80-89 23 (13.86)   46 (14.11)
Mean 69.6 68.3
TABLE 2. Primer sequences for genotyping SNPs of GSTP1, GSTM1, and GSTT1
Primer Primer sequence (5’→3’) Product size/Regions
GSTP1
　rs1695-AGF CCTGGTGGACATGGTGAATGAC rs1695
　rs1695-AGR CAGATGCTCACATAGTTGGTGTAGA
　rs1695-AGV1 TGCAAATACATCTCCC (VIC dye)
　rs1695-AGM1 TGCAAATACGTCTCCC (FAM dye)
GSTM1
　GSTM1-F GAACTCCCTGAAAAGCTAAAGC 218 bp
　GSTM1-R GTTGGGCTCAAATATACGGTGG /exon 7 deletion
GSTT1
　GSTT1-F TTCCTTACTGGTCCTCACATCTC 459 bp
　GSTT1-R TCACCGGATCATGGCCAGCA /intron 4 deletion
SNP: single-nucleotide polymorphism, GST: glutathione-S-transferases
drocarbons, such as the smoke carcinogen benzopyrene, 
whereas GSTT1 detoxifies smaller reactive hydrocarbons, 
such as ethylene oxide. The GSTM1 null genotype has a de-
creased capacity to detoxify certain carcinogens and has 
been linked with an increased risk for solid tumors [8,9]. 
Examination of the GSTT1 gene may provide insights into 
the dangers of exposure to common environmental or diet-
ary agents that produce chromosomal damage. Indeed, 
persons with the GSTT1 null genotype show a reduced abil-
ity to detoxify the metabolites of ethylene oxide [7]. The 
GSTT1 null genotype has been associated with increased 
risk for ovarian, bladder, and lung cancers [10-13]. How-
ever, other studies have not confirmed the association be-
tween the GSTT1 null genotype and cancer. The aim of this 
study was to investigate the association between the 
GSTP1, GSTM1, and GSTT1 genotypes and the risk of 
prostate cancer in Korean men.
MATERIALS AND METHODS
1. Patients and DNA samples
The DNA samples were provided by the Biobank of Won-
kwang University Hospital, which is a member of the 
National Biobank of Korea; this Biobank is supported by 
the Ministry of Health, Welfare and Family Affairs. After 
approval from the institutional review board and informed 
consent from the participants, genomic DNA was obtained 
from 166 patients with prostate cancer and from 327 
healthy controls. The healthy controls were selected by 
having a prostate-specific antigen (PSA) value below 2.5 
ng/ml, a normal digital rectal examination, and no hypo-
echoic lesions in transrectal ultrasonography (TRUS). The 
mean age in the cancer group was 69.6 years (range, 51-87 
years), and the mean age in the healthy controls was 68.3 
years (range, 50-86 years) (Table 1). Genomic DNA was ex-
tracted from the leukocytes of the peripheral blood by means 
of a standard phenol-chloroform method or with the use of 
a Genomic DNA Extraction kit (iNtRON Biotechnology, 
Korea) according to the manufacturer's directions. The di-
agnosis of prostate cancer was histologically confirmed by 
TRUS-guided prostate biopsy. The patients were classified 
on the basis of tumor stage and grade.
2. Genotype analysis with the Taq-Man probe
The assay reagents for rs1695 and rs1138272 in the GSTP1 
gene were designed by Applied Biosystems (Applied 
Biosystems, USA). The reagents consisted of a 40x mix of 
unlabeled polymerase chain reaction (PCR) primer and 
TaqMan MGB probes (FAM and VIC dye-labeled). The re-
action in 10 μl was optimized to work with 0.125 μl 40x re-
agents, 5 μl 2x TaqMan Genotyping Master mix (Applied 
Biosystems, USA), and 2 μl (50 ng) of genomic DNA. The 
PCR conditions were as follows: one cycle at 95
oC for 15 min 
and 40 cycles at 95
oC for 10 s and 60
oC for 45 s. The PCR 
was performed in the Rotor-Gene thermal cycler RG6000 
(Corbett Research, Australia). The samples were read and 
analyzed by using the Rotor-Gene 1.7.40 software (Corbett 
Research, Australia).
3. Genotype analysis by PCR
The GSTT1 and GSTM1 genotypes were determined by PCR. 
The primer pairs used for PCR amplification were 5’-GAAC 
TCCCTGAAAAGCTAAAGC-3’ and 5’-GTTGGGCTCAAA 
TATACGGTGG-3’ for GSTM1 and 5’-TTCCTTACTGGTC 
CTCACATCTC-3’ and 5’-TCACCGGATCATGGCCAGCA- 
3’ for GSTT1 (Table 2). PCR reactions were carried out for 
30 cycles, each including a 10-s denaturation step at 98
oC, 
a 15-s annealing step at 60
oC, and a 20-s extension step at Korean J Urol 2011;52:247-252
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FIG. 1. Methods and results - glutathione-S-transferaseM1. PCR:
polymerase chain reaction.
FIG. 2. Methods and result - glutathione-S-transferaseT1. PCR: 
polymerase chain reaction.
TABLE 3. Genotype and allele analysis of GSTP1 polymorphisms
in patients with prostate cancer and controls
Position
Genotype
/Allele
No. of 
control (%)
No. of 
PC (%)
p-value
vs. PC
g.1375A＞G AA 209 (63.91) 117 (70.48) 0.346
 (rs1695) AG 101 (30.89)   42 (25.30)
GG 17 (5.20)   7 (4.22)
A 519 (79.76) 276 (83.13) 0.077
G 135 (20.64)   56 (16.87)
Calculated from the translation start site. GST: glutathione-S- 
transferase, PC: prostate cancer
TABLE 4. Association between GSTM1 and GSTT1 genotypes and
prostate cancer
No. of 
prostate 
cancer (%)
No. of 
control (%)
OR (95% CI)
p-
value
GSTM1
  Null 90 (54.22) 125 (38.23) 1.53 (1.20-1.96)
a 0.001
  Present 76 (45.78) 202 (61.77)
GSTT1
  Null 85 (51.20) 163 (49.85) 1.04 (0.81-1.33) 0.849
  Present 81 (48.80) 164 (49.80)
The data were analyzed by the chi-square test. GST: glutathione-
S-transferase, OR: odds ratio, CI: confidence interval, 
a: p＜0.05
TABLE 5. Correlation of the clinical and pathological features of
prostate cancer with GSTP1 genotypes
Pathological features
GSTP1
p-
value No. of 
A/A (%)
No. of 
A/G (%)
No. of 
G/G (%)
Stage
  High (≥T3 or N1 or M1) 55 (70.5) 21 (26.9) 2 (2.6) 0.407
  Low (T1-T2 or No or M0) 62 (70.5) 21 (23.9) 5 (5.7)
Gleason score
  ≥7 89 (71.8) 31 (25.0) 4 (3.2) 0.226
  ≤6 28 (66.7) 11 (26.2) 3 (7.1)
The data were analyzed by the chi-square test. GST: glutathione-
S-transferase
72
oC. The PCR program included an initial denaturation 
time of 5 minutes at 95
oC and an extension time of 10 mi-
nutes at 72
oC after the last cycle. The PCR products were 
separated by electrophoresis by using a 2% agarose gel and 
were visualized by ethidium bromide staining. The pres-
ence of bands at 218 and 459 bp corresponded to intact ge-
nomic GSTM1 (Fig. 1) and GSTT1 (Fig. 2), respectively, 
whereas the absence of the bands implied the null state. 
4. Statistical analysis
The correlations between the GSTP1, GSTM1, and GSTT1 
genotypes and clinico-pathological factors for prostate can-
cer were analyzed by using SPSS ver. 15.0 (SPSS Inc., Chi-
cago, IL, USA) and analyze software (Dynacom, Yokohama, 
Japan). The chi-square test was used to calculate the p-val-
ues and 95% confidence intervals (95% CIs) for the odds ra-
tios (ORs).
RESULTS
Among the GSTP1 polymorphisms, two single-nucleotide 
polymorphisms (SNPs; rs1695 and rs1138272) were se-
lected for large sample genotyping on the basis of their 
locations. The genotype and allele frequencies of rs1695 
(g.1375A＞G, based on NC_000011.9) were not significantly 
different between the patients with prostate cancer and the 
healthy controls (Table 3). The SNP rs1138272 (g.2265C＞
T), from the NCBI SNP database, was also analyzed for 
genotype; however, when 96 samples were analyzed, there 
was only one genotype. These findings suggest that the 
rs1138272 of GSTP1 might be a very rare polymorphism 
or a monomorphism in the Korean population.
　The frequencies of the GSTM1 null and GSTT1 null 
genotypes were 38.2% and 49.8% in the control population 
and 54.2% and 51.2% in the prostate cancer group, respec-
tively. The GSTM1 null genotype was more common in the Korean J Urol 2011;52:247-252
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TABLE 6. Correlation of the clinical and pathological features of prostate cancer with GSTM1 genotypes
Pathological features
GSTM1
OR (95% CI) p-value
No. of null (%) No. of present (%)
Stage
　High (≥T3 or N1 or M1) 39 (50.0) 39 (50.0) 1.51 (0.82-2.80) 0.212
　Low (T1-T2 or No or M0) 53 (60.2) 35 (39.8)
Gleason score
　≥7 68 (54.8) 56 (45.2) 1.10 (0.54-2.23) 0.858
　≤6 24 (57.1) 18 (42.9)
The data were analyzed by the chi-square test. GST: glutathione-S-transferase, OR: odds ratio
TABLE 7. Correlation of the clinical and pathological features of prostate cancer with GSTT1 genotypes
Pathological features
GSTT1
OR (95% CI) p-value
No. of null (%) No. of present (%)
Stage
　High (≥T3 or N1 or M1) 40 (51.3) 38 (48.7) 0.79 (0.43-1.46) 0.453
　Low (T1-T2 or No or M0) 40 (45.5) 48 (54.5)
Gleason score
　≥7 58 (46.8) 66 (53.2) 1.25 (0.62-2.52) 0.530
　≤6 22 (52.4) 20 (47.6)
The data were analyzed by the chi-square test. GST: glutathione-S-transferase, OR: odds ratio
prostate cancer group than in the control group (OR=1.53, 
95% CI=1.20-1.96) (Table 4). No statistically significant 
correlations were identified between the GSTP1, GSTM1, 
and GSTT1 genotypes and staging or Gleason score (Table 
5-7).
DISCUSSION
Prostate cancer is a multifactorial disease that likely in-
volves both environmental and genetic factors. Collectively, 
most putative environmental and genetic risk factors have 
not shown a consistent association with prostate cancer 
risk, and little is known about the interaction of these 
factors. Prostate cancer risk varies most prominently with 
age, ethnicity, family history, and diet [14].
　Individual differences in the susceptibility to carcino-
gens play an essential role in the development of sporadic 
cancer. The biochemical basis for the genetic susceptibility 
to environmental hazards is related to genetic polymorphi-
sms that normally occur in the general population and in-
volves a series of genes implicated in the metabolic activa-
tion or detoxification of environmental genotoxins. Several 
polymorphic genes encoding enzymes involved in the bio-
transformation of carcinogens have been studied as possi-
ble prostate cancer risk modifiers, including the GST sys-
tem and the phase I cytochrome P450 (CYP) genes [15]. 
　The GSTs are involved in the metabolism of a wide varie-
ty of potential carcinogens. The levels of GST isozymes in 
normal and tumor tissues are important for several rea-
sons. High levels of GST have been shown to detoxify sev-
eral chemical carcinogens efficiently and to protect tissues 
against DNA damage. The presumptive function of GST is 
to protect tissues against toxic or carcinogenic compounds 
that enter the body as food components, food additives, or 
drugs [4-7]. Considerable evidence suggests the existence 
of various biological defense systems against carcinogenesis. 
Individuals with homozygous deletions of the GSTM1, 
GSTT1, and GSTP1 genes lack GST and therefore may be 
unable to eliminate electrophilic carcinogens efficiently, 
which may increase the risk of somatic mutations that lead 
to tumor formation [8-13,16]. The phenotypic absence of 
GSTM1, GSTT1, and GSTP1 activities is due to homozygous 
inherited deletions of these genes, which is referred to as 
the null genotype [17].
　Several population-based studies have reported preva-
lences ranging from 47% to 58% for the GSTM1 deletion 
genotype and from 13% to 25% for the GSTT1-null geno-
type among Caucasian Europeans. For GSTP1, the preva-
lences of Ile/Val heterozygosity and Val/Val homozygosity 
were found to be between 38% and 45.7% and between 7% 
and 13%, respectively. Previous studies have shown that 
the GSTM1 null genotype correlates with increased sus-
ceptibility to bladder and prostate cancers, as well as to 
lung cancer [18,19].
　In a Southern European population, an analysis of the 
frequencies of the 670 alleles indicated that men carrying 
two B-alleles (GSTM3) have an increased risk for prostate 
cancer. The polymorphism in GSTM3 may be an important 
biomarker for prostate cancer risk, especially in the defi-
nition of the genetic risk profile of populations of Southern 
Europe [20]. In Chilean prostate cancer patients, the fre-
quency of the m2 variant allele and GSTM1(−/−) showed Korean J Urol 2011;52:247-252
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statistically significant increases compared with the con-
trol group. Chilean people carrying single or combined 
GSTM1 and CYP1A1 polymorphisms are more susceptible 
to prostate cancer [21]. In a Brazilian population, the GST 
and CYP1A1 genotypes were not associated with the sus-
ceptibility to prostate cancer or its outcome. Those authors 
said that they were unable to demonstrate any relationship 
between genotypes and parameters of aggressiveness at di-
agnosis or during the follow-up. Also, there was no relation-
ship between the response to radiotherapy and any other 
outcome [22].
　In a Japanese population, the frequency of the GSTM1 
null genotype was also slightly higher in prostate cancer 
patients (49.6%) compared with the control value (42.5%), 
with an OR of 1.2 (95% CI=0.78-1.99). A GSTT1-positive 
genotype was thus associated with a 60% higher risk in the 
prostate cancer group (OR 1.6; 95% CI=0.99-2.51). That 
study showed a significant relation between the prostate 
cancer group and the genetic polymorphisms of CYP1A1 
alone and in combination with GSTM1 [23]. The GSTP1- 
313 G polymorphism, and null alleles of GSTM1 and GSTT1, 
are strong predisposing risk factors for sporadic prostate 
cancer in North India [24]. 
　In the present study, we investigated the potential link 
between the GSTM1, GSTT1, and GSTP1 null genotypes 
and prostate cancer risk. The results of our study showed 
an association between prostate cancer risk and the pres-
ence of the GSTM1 null genotype (Table 3). These results 
suggest that elevated metabolic activation and decreased 
levels of detoxification of endogenous or exogenous carci-
nogens increase DNA adduct formation, thereby increas-
ing the prostate cancer risk [1,19]. 
　The major finding of the present meta-analysis provides 
support for the association of the genetic polymorphism of 
GSTM1 (null vs. non-deleted) with the susceptibility to 
prostate cancer. However, the GSTT1 polymorphism (null 
vs. nondeleted) and the GSTP1 polymorphism showed no 
correlation with prostate cancer risk [19]. Although the re-
sults of our study show a statistically significant associa-
tion between the GSTM1 polymorphisms and prostate can-
cer, the clinical significance of this finding requires further 
investigation. 
　There was no significant association between the GSTP1, 
GSTM1, and GSTT1 genotypes and the clinico-pathologic 
factors of prostate cancer. To better understand the role of 
the GSTs and to study their predictive value, tumor prog-
nostic criteria should be examined, such as cancer-specific 
survival and overall survival.
CONCLUSIONS
An increased risk for prostate cancer may be associated 
with the GSTM1 null genotype in Korean men, but no asso-
ciation was found with the GSTT1 or GSTP1 phenotype. 
To better understand the role of the GSTs and to study their 
predictive value, tumor prognostic criteria should be exam-
ined, such as cancer-specific survival and overall survival.
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